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Abstract. Nanotechnology for cancer gene therapy is an 
emerging field. Nucleic acids, polyamine analogues and 
cytotoxic products of polyamine oxidation, generated 
in situ by an enzyme-catalyzed reaction, can be developed 
for nanotechnology-based cancer therapeutics with reduced 
systemic toxicity and improved therapeutic efficacy. Nucleic 
acid-based gene therapy approaches depend on the compac-
tion of DNA/RNA to nanoparticles and polyamine analogues 
are excellent agents for the condensation of nucleic acids to 
nanoparticles. Polyamines and amine oxidases are found in 
higher levels in tumours compared to that of normal tissues. 
Therefore, the metabolism of polyamines spermidine and 
spermine, and their diamine precursor, putrescine, can 
be targets for antineoplastic therapy since these naturally 
occurring alkylamines are essential for normal mamma-
lian cell growth. Intracellular polyamine concentrations 
are maintained at a cell type-specific set point through the 
coordinated and highly regulated interplay between biosyn-
thesis, transport, and catabolism. In particular, polyamine 
catabolism involves copper-containing amine oxidases. 
Several studies showed an important role of these enzymes 
in developmental and disease-related processes in animals 
through the control of polyamine homeostasis in response to 
normal cellular signals, drug treatment, and environmental 
and/or cellular stress. The production of toxic aldehydes and 
reactive oxygen species (ROS), H2O2 in particular, by these 
oxidases suggests a mechanism by which amine oxidases can 
be exploited as antineoplastic drug targets. The combination 
of bovine serum amine oxidase (BSAO) and polyamines 
prevents tumour growth, particularly well if the enzyme has 
been conjugated with a biocompatible hydrogel polymer. The 
findings described herein suggest that enzymatically formed 
cytotoxic agents activate stress signal transduction pathways, 
leading to apoptotic cell death. Consequently, superparamag-
netic nanoparticles or other advanced nanosystem based on 
directed nucleic acid assemblies, polyamine-induced DNA 
condensation, and bovine serum amine oxidase may be 
proposed for futuristic anticancer therapy utilizing nucleic 
acids, polyamines and BSAO. BSAO based nanoparticles 
can be employed for the generation of cytotoxic polyamine 
metabolites.
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1. Introduction
Nanotechnology, concerning particles and devices in the range 
of 1-100 nm dimension, provides new opportunities in cancer 
therapy. Nanoparticle based therapies have been shown to 
reduce systemic toxicities and improve therapeutic efficacy of 
drugs (1). Doxil (liposomal-polyethylene glycol doxorubicin), 
DanoXome (liposomal daunorubicin), Oncaspar (Polyethylene 
glycol-L-Asparaginase), and Abraxane (albumin-bound pacli-
taxel) are FDA approved therapeutic nanoparticles. There 
are many nanoparticle-based agents in clinical trials aimed 
at reducing the toxicity of chemotherapeutic drugs, such as 
paclitaxel, camptothecin, doxorubicin, and cisplatin (1-4). 
In addition, nanotechnology for cancer gene therapy is an 
emerging field (5). Non-viral vectors for nanoparticle-based 
gene therapeutics are expected to overcome limitations due to 
pathogenicity and immunogenicity of viral vectors. This review 
introduces advances in the research of novel nanoparticles 
based on directed nucleic acid assemblies and polyamine-
induced DNA nanoparticles as well as bovine serum amine 
oxidase-based nanoparticles to overcome some of the problems 
associated with conventional anticancer therapy, including the 
limitations of treating drug resistant tumours.
2. Nucleic acid assemblies and their use as drug delivery 
vehicles
Nucleic acids are the fundamental molecules of life and the 
complementarity of base pairing allows them to direct informa-
tion transfer and cellular functions. DNA helices are inherently 
nanoscale building blocks with a diameter of approximately 
2 nm, a helical repeat of 3.4 nm (10.5 base pairs) and a persis-
tence length of approximately 50 nm (4). Inspired by the Holliday 
junction, a four-way junction intermediate observed during 
recombination (6), Seeman first proposed thermodynamically 
stable four-way junctions with sticky ends and built double 
cross-over and triple cross-over motifs (7). Two-dimensional 
lattice, and polyhedral DNA structures such as the cube, six-
connected network, pentagonal dodecahedron and truncated 
octahedron were also designed by Seeman and others (8,9). The 
tile structures further helped to build double-double crossovers 
and 3-, 4-, 6-, 8-, and 12-helix DNA tile complexes (10-12). 
Nanogrids, nano ribbons, and nanotubes were created in this 
manner. Three point stars, six-point stars, and T-shaped junc-
tions increased the versatility of nano structures based on 
tile-based self-assembly (12-14). T-shaped structures can give 
rise to orthogonal co-ordinated ladders, lattices and polar 
coordinated wheels (14).
The design process in tile-based DNA engineering is tedious 
with the assembly requiring strictly balanced stoichiometry, 
and the structures are limited by the length of the synthetic 
oligonucleotides (4). ‘DNA origami’ is a more recent and 
versatile method, first developed by Rothemund (15). The term 
origami refers to the Japanese folk art of folding paper into a 
special shape (9,15). In this method, one long strand of single-
stranded DNA (7.3 kb bacteriophage M-13 DNA) is folded to 
produce the desired structure by the help of smaller (32 bp) 
staple strands. The small staple strands are complementary to 
at least two distinct segments of the long single stranded DNA. 
The long single stranded DNA and an excess of staple strands 
are heat-annealed to form the origami. The origami method is 
formulated to yield 2-dimensional and 3-dimensionl structures 
and use double stranded DNA. Other investigators (16,17) 
reported the formation of multi-domain DNA origami by 
using origami four-way junctions. DNA origami can also be 
used as a template for patterns using streptavidin molecules 
or enhanced green fluorescent protein (18,19). Hung et al (20) 
reported the positioning of gold nanoparticles on lithographi-
cally confined DNA origamies. Development of a molecular 
robot consisting of a DNA walker that moves on top of an 
origami in a programmed path and collects specified cargo 
is another advancement in this field (21-23). Strategies have 
been developed to make 3D structures such as three, four and 
six sided prisms (24) icosahedrons (25), 3D DNA box with an 
openable lid (26), 3D DNA box origami (27) and a tetrahedron 
DNA container (28).
A new route to building three dimensional nanostructures 
has been opened by the development of DNA bricks analogous 
to the LEGO building model (29). The basic building block in 
the structures is a 32-nucleotide single-stranded DNA which 
contains four regions that can hybridize to four neighbouring 
DNA strands. To build 3D structures, DNA bricks resembling 
two-stud LEGO bricks are connected with 90˚ left-handed 
turn, resulting in layers of bricks that are shifted 90˚ relative to 
each other. Whereas LEGO structures are assembled by hand, 
brick by brick, the DNA structures form by self-assembly. 
Each DNA brick is encoded with an individual sequence that 
determines its position and allows the structure to assemble by 
hybridization of complementary strands. In a one-step proce-
dure, a cuboid structure is formed in ~72 h. By creating empty 
boxes and open-cavity shapes, tunnels of varying width, depth, 
and geometry authors allude to many types of functional 
nanodevices including drug-delivery vehicles (29).
Several research groups have explored the possibility of 
using 3-dimensional nanocontainers as delivery vehicles. 
Erben et al (30) demonstrated the encapsulation of cyto-
chrome c within a DNA tetrahedral cage, where the protein 
molecule is conjugated to the 5'-end of one of the DNA strands 
via a surface amine. The ability of a DNA origami nanocage to 
encapsulate Au nanoparticles with various sizes has also been 
demonstrated (31). Anderson et al (32) created a nanoscale box 
with a cavity large enough to contain a ribosome and a control-
lable lid. Douglas and collaborators (33) engineered a DNA 
capsule fitted with aptamers that can be loaded with molecular 
cargo and unloaded upon binding to a desired target cell. DNA 
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icosahedron structures were also designed and constructed as 
smart drug delivery vehicles (34). Taken together, these studies 
provide the initial proof-of-principle for developing and using 
DNA nanocontainers for drug delivery.
3. Polyamines and their role in DNA condensation to nano­
particles
Polyamines are polycationic biogenic amines required for 
both eukaryotic and prokaryotic cell growth and differ-
entiation (35,36). The natural polyamines (putrescine 
[NH2(CH2)4NH2], spermidine [NH2(CH2)4NH(CH2)3NH2] 
and spermine [NH2(CH2)3NH(CH2)4NH(CH2)3NH2]) are 
formed from the decarboxylation products of ornithine and 
S-adenosyl-methionine in nearly all eukaryotic cells. In normal 
cells, polyamine concentrations are highly regulated by the 
action of biosynthetic and catabolising enzymes, such as orni-
thine decarboxylase (ODC) and spermidine/spermine acetyl 
transferase; however, polyamine levels are elevated in cancer 
cells (36). Motives for these increased levels include enhanced 
putrescine synthesis from ornithine by ODC, the rate-limiting 
enzyme, and an increased uptake of polyamines (37). However, 
in situations of over-accumulation or depletion of intracellular 
polyamine pools, cell death can occur (38,39). Polyamines 
attract interest because of their multiple functions in cell 
biology, including cell cycle regulation, gene expression and 
signal transduction (40-43). The primary role of polyamines 
in regulating cell proliferation and cell death have prompted 
scientists to investigate the role of these compounds in mito-
chondria, multifunctional organelles participating in a range 
of cellular processes, such as energy production, proliferation, 
senescence and death (44). Mitochondria apparently lack a 
polyamine biosynthetic pathway, nevertheless substantial 
quantities of spermine and spermidine have been detected in 
the mitochondrial matrix and a specific mitochondrial poly-
amine transporter has been described (45).
In addition to their biological and gene regulatory roles, 
polyamines provoke the condensation of DNA on nanopar-
ticles (46,47). Condensation is an essential process for the 
packaging of DNA in cells. Hence, the mechanism of DNA 
condensation by polyamines and other multivalent cations has 
been an active area of research for the past forty years (48). 
This phenomenon has acquired further importance because 
condensed DNA can be transported into cells more efficiently 
than uncondensed DNA (47). Polycations such as polyethyl-
eneimine, polylysine and cationic lipids have been used as 
DNA delivery agents in cells. These cations cause localized 
bending or distortion of DNA at a critical extent of charge 
neutralization, facilitating the formation of rods and toroid-like 
structures (49). Carlstedt et al (50) suggested that the association 
of DNA with polycations or surfactants might be manifested 
as compaction, a conformational change of single DNA chain 
from an extended coil to a compact globule or macroscopic 
phase separation, depending on the conditions. Although the 
general term condensation also covers compaction, conden-
sation generally involves multiple DNA molecules. Beyond 
DNA condensation, an increased concentration of spermine 
on DNA result in phase separation. A miscibility gap has been 
found and the lower boundary of the phase separation region 
occurred at a spermine:DNA charge ratio close to unity (51). 
With a large excess of spermine at charge ratios >120, clear 
solutions are formed beyond miscibility gap. Other studies 
also showed similar miscibility gaps in DNA mixtures with 
surfactants or cyclodextrins at much lower charge ratios than 
spermine (50). The ability of PEI, poly-L-lysine, surfactants, 
and cyclodextrins to condense DNA and the hydrodynamic 
properties of DNA nanoparticles produced by these agents 
have been characterized (52,53). Structural specificity effects 
have been demonstrated in polyamine-mediated DNA conden-
sation and oligonucleotide uptake in cells (54,55). Polyamines 
and oligonucleotides also exert a synergistic inhibition of the 
transcription of targeted genes (55).
4. Amine oxidases and their utilization in nanomedicine
Polyamines are substrates for a large class of enzymes, the 
amine oxidases (AOs), including spermine oxidase and poly-
amine oxidases (PAOs). AOs regulate the level of polyamines 
in the cell. For example, PAOs are involved in polyamine 
homeostasis, while the other oxidases are important for the 
terminal catabolism of polyamines, i.e. they catalyse the forma-
tion of metabolites, like ammonia and amino acids, which are 
excreted through the kidney (56). These enzymes operate by 
abstracting two electrons from primary amines and transfer-
ring them to molecular oxygen to produce the corresponding 
aldehyde, ammonia and hydrogen peroxide, according to the 
following equation:
   Amine Oxidase R-CH2-NH3+ + O2 + H2O -------------------▶ R-CHO + NH4+ + H2O2
The superfamily of AOs represents an important class of 
enzymes, which are present in numerous living systems. These 
enzymes differ with respect to their molecular architecture, 
catalytic mechanisms, and patterns of substrate specificity, 
inhibitor sensitivity, and subcellular localizations (57). In 
the most common classification, these enzymes (amine: 
oxygen oxidoreductases, AOs, E.C. 1.4.3.4.) are divided into 
two classes, based on the chemical nature of the cofactors 
involved (58). The first class is characterized by the pres-
ence of flavin adenine dinucleotide (FAD; FAD-AOs) and is 
ubiquitous in most mammalian species, whereas PAOs are 
found principally in vertebrates and plants (59). The second 
class consists of enzymes having a tightly bound Cu2+ ion and 
a carbonyl-type group identified as either a 6-hydroxydopa 
quinone (2,4,5-trihydroxyphenylalaninequinone, TPQ) or a 
lysine tyrosylquinone (LTQ) at their active site. TPQ is easily 
detected due to its pink absorption in the visible region, approx-
imately at 480 nm (60). FAD- and Cu2+/TPQ-amine oxidases 
have been isolated and characterized from numerous organ-
isms, ranging from microorganisms, plants and mammals. 
FAD-AOs are mainly intracellular enzymes, often associated 
with the outer mitochondrial membrane (61,62), whereas 
CuAOs are either intra- or extra-cellular enzymatic proteins, 
or in some cases integral plasma membrane proteins (63-65).
A peroxisomal FAD-dependent enzyme, N1-acetylpoly-
amine oxidase (APAO), is a constitutively expressed enzyme 
that catalyses the cleavage of acetylated polyamines to produce 
spermidine (from spermine) or putrescine (from spermidine), 
3-aceto-aminopropanal and H2O2. Wang et al (66) identified 
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a gene (PAOh1) for an enzyme capable of oxidizing unsub-
stituted spermine. Vujcic et al (67) subsequently confirmed 
that this new gene/enzyme was also involved in the polyamine 
catabolic pathway. The new enzyme, named SMO is a highly 
inducible FAD-dependent enzyme that oxidizes spermine to 
produce spermidine, 3-aminopropanal and H2O2. Subsequent 
studies indicated that SMO might represent a target for chemo-
prevention (68). In fact, using tumor-necrosis factor (TNFα), 
a pleiotropic inflammatory cytokine, it was shown that this 
general mediator of inflammation was able to stimulate SMO 
activity, resulting in a potential damage induced by reactive 
aldehydes and ROS. The aldehyde, 3-aminopropanal, and 
H2O2, once converted into the highly reactive hydroxyl radical 
(HO•) through Fenton-like-catalysis, can damage RNA, DNA, 
membranes and proteins. A severe damage to DNA, by both 
enzymatic oxidation products, can lead to mutagenic changes 
necessary for the development and progression of multiple 
epithelial cancers. In addition, H2O2 formed by polyamine 
catabolism might play a role as a signaling molecule (69,70).
5. Cell killing by polyamines and BSAO
Attempts to exploit polyamine metabolizing enzymes as thera-
peutic targets, as well as to utilise the polyamine backbone 
as pharmacophore for the design of anticancer drugs have 
been investigated and reviewed (71,72). Our findings showed 
the possibility of using purified BSAO in the presence of 
exogenous spermine or endogenous polyamines to induce cyto-
toxicity (73). The mechanism of cell death induced by BSAO 
and spermine, in the extracellular environment was examined 
on human colon adenocarcinoma and melanoma cell lines, 
either drug-sensitive or multidrug resistant (MDR) (74,75). 
The oxidation products of polyamines, H2O2 and aldehyde(s), 
have been implicated in programmed cell death, induction of 
cytotoxicity and inhibition of cell division (76,77). Cytotoxic 
metabolites of spermine formed in situ by an enzyme-catalyzed 
reaction might be useful for the destruction of tumours (Fig. 1). 
An important distinction between normal and tumour cells is 
related to polyamine content and metabolism; in general poly-
amine concentrations are high in rapidly growing tissues such 
as tumours (78). However, AO activity has a contrasting effect 
on cancer cells. On the one hand it inhibits cell growth and 
induces cell death by necrosis (79) and/or apoptosis (74,80); 
on the other hand, AO activity has been correlated with cancer 
progression particularly when it is enhanced. Therefore, the 
involvement of AOs in cancer is associated with two different 
aspects: the direct regulation of the level of biogenic amines 
in cells and the formation of cytotoxic catabolites, i.e. H2O2 
and aldehydes (74,79). Recently, several aspects of the role of 
AOs in cancer have been taken deeply into consideration by 
Toninello and collaborators (81).
The cytotoxicity induced by BSAO in the presence of 
exogenous spermine was evaluated in both colon adenocar-
cinoma LoVo WT and LoVo DX cell lines as a function of 
spermine concentration as well as of exposure time, at 37˚C. 
Table I shows the percentage of cell survival as a function of 
exogenous spermine concentration up to 15 µM in the pres-
ence of BSAO, after 60 min of incubation. Multidrug-resistant 
(MDR) cells are more affected by treatment with spermine 
compared to their drug-sensitive counterparts. For instance, 
at 6 µM spermine concentration, the survival of LoVo WT 
cells was approx. 45%, while only a very low percentage 
of ~7.5% in LoVo DX cells maintained their viability. To 
evaluate the contribution of H2O2 to cytotoxicity, with respect 
to other enzymatic oxidation products, experiments were 
carried out in the presence of catalase. Catalase is a hydrogen 
peroxide-scavenging enzyme which converts H2O2 into water 
and oxygen. There was a remarkable ~80% reduction of 
cytotoxicity in both cell lines, apparently due to the clearance 
of H2O2 by catalase. However, this result shows that H2O2 is 
Table I. Clonogenic assay: dose response.
 % Cell survival in cell lines ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Spermine (µM) LoVo WT LoVo DX M14 WT M14 ADR
  0 100.0±0.0 100.0±0.0 100.0±0.0 100.0±0.0
  3 84.0±5.09 29.0±4.30 77.1±4.5 68.8±3.53
  6 45.0±6.70 7.5±1.30 37.1±1.5 18.8±0.98
12 1.7±0.62 0.2±0.02 14.6±3.1 10.4±0.56
15 0.4±0.02 0.1±0.09 5.6±0.1 2.6±0.18
Effect of exogenous spermine concentration (0-15 µM) on percentage cell survival in LoVo WT, LoVo DX, M14 WT and M14 ADR in the 
presence of BSAO (6.54x10-3 U/ml), during 60 min of incubation at 37˚C. Means and SDs are shown for two to five estimations from four to 
six experiments.
Figure 1. Reaction scheme for spermine oxidation in the presence of BSAO.
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not the exclusive toxic agent and that other species might be 
involved, such as acrolein. In order to determine the contri-
bution of aldehydes in provoking the cytotoxicity by BSAO/
spermine, catalase and NAD-dependent aldehyde dehydro-
genase (ALDH) were added to the incubation mixture. In 
these experimental conditions, cytotoxicity was completely 
inhibited throughout the 60 min of incubation (Table II). 
MDR human melanoma cells were more sensitive than the 
corresponding wild-type cells at all spermine concentrations 
tested. At the 6 µM spermine concentration, survival of M14 
WT cells was 37.1%, while only 18.8% of the M14 ADR cells 
remained viable (Table I). As single agents, BSAO or spermine 
were not toxic to either cell line up to 15 µM spermine.
The morphological and ultrastructural changes induced by 
treatment with BSAO/spermine were investigated by scanning 
(SEM) and transmission electron microscopy (TEM) to gain 
insight into the mechanism(s) responsible for the higher cyto-
toxic effect in MDR cells compared to drug-sensitive cells. 
Fig. 2 shows electron microscopic images of control M14 WT 
(panel a) and M14 ADR (panel b) cells, respectively, grown at 
37˚C. These cells have elongated or polygonal shape and their 
surface are covered by randomly disseminated microvilli. 
Table II. Clonogenic assay: time course.
 % Cell survival in cell lines --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Time (min) LoVo WT (1) LoVo DX (2) LoVo WT (3) LoVo DX (4)
  0 100.0±0.0 100.0±0.0 100.0±0.0 100.0±0.0
  5 76.0±12.2 45.0±3.8 104.0±7.5 106.0±11.3
10 53.0±10.4 27.0±2.4 102.0±18.3 98.2±8.1
15 43.0±3.9 24.7±2.1 99.2±2.4 98.0±16.5
20 40.2±6.8 21.0±4.9 97.0±3.7 97.0±7.9
30 31.2±5.2 13.7±8.1 97.3±5.1 96.0±8.6
40 20.2±3.3 8.9±1.6 96.8±2.3 95.3±12.9
60 18.4±1.5 4.8±1.4 96.0±6.4 94.0±2.8
Effect of catalase and ALDH on cytotoxicity induced by BSAO in the presence of spermine. LoVo WT and LoVo DX cells were incubated at 
37˚C, up to 60 min, with BSAO (6.54x10-3 U/ml) and exogenous spermine 12 µM, in absence of inhibitors (columns 1 and 2), or with catalase 
(240 U/ml) and ALDH (0.4 U/ml) (columns 3 and 4). Means and SDs are shown for two to five estimations from four to six experiments.
Figure 2. Effect of exposure to BSAO and spermine on the morphology of M14 WT and M14 ADR cells (scanning electron micrographs). (a) Untreated 
M14 WT cells. (b) Untreated M14 ADR cells. (c) M14 WT cells exposed for 60 min to 6.5x10-3 IU/ml BSAO and 6 µM spermine at 37˚C. (d) M14 ADR cells, 
same treatment as in (c). Bars: 10 µm. From Agostinelli et al (74).
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After treatment with BSAO/spermine (6 µM) at 37˚C, cells 
from both cell lines (images c and d) appear less elongated than 
untreated control; some of them tended to become rounded 
with numerous blebs on their surface. These cells had a 
tendency to detach from the substrate. Both M14 WT and M14 
ADR control cells, grown at 37˚C, showed a well-preserved 
ultrastructure when observed by TEM. The cytoplasm was 
characterized by the presence of numerous mitochondria with 
parallel cristae in a dense and uniform matrix (Fig. 3a and b). 
After exposure to BSAO/spermine (6 µM) at 37˚C, M14 WT 
cells did not show any consistent aberration but some mito-
chondrial display dilated cristae (Fig. 3c). The alterations of 
mitochondria structure were much more evident in MDR 
cells; in particular, they showed a highly condensed matrix 
and vacuolised cristae (Fig. 3d). Similar morphological modi-
fications and ultrastructural alterations were also observed in 
both LoVo colon adenocarcinoma cell lines, where MDR cells 
showed all the mitochondria visibly damaged.
Since mitochondria appear to play a pivotal role in 
determining the differential response between sensitive and 
drug-resistant cells, a flow cytometric study was carried out 
on LoVo cells to generate information on the mitochondrial 
activity. The results showed a basal hyperpolarized status of 
the mitochondria in control MDR LoVo cells. After the treat-
ment with BSAO/spermine, the higher sensitivity to cytotoxic 
spermine derivatives observed in adenocarcinoma LoVo 
DX cells compared to their sensitive counterparts, has been 
therefore attributed to an earlier and higher mitochondrial 
membrane depolarisation. Moreover, a higher basal production 
of ROS was detected in MDR cells than that in drug-sensitive 
cells, suggesting an increased mitochondrial electron transport 
chain (METC) activity in MDR cells (79,82).
6. Hyperthermia in combination with polyamine meta­
bolites in therapeutic applications
Hyperthermia is an alternate to cytotoxic drug therapy. 
Conventional cancer chemotherapy encounters several difficul-
ties, including poor selectivity of the cytotoxic drugs and the 
development of MDR in the course of drug treatment. The 
term “hyperthermia” is generally used to imply a treatment 
based on the generation of heat at the tumour site (83). This 
approach involves raising the temperature of local environ-
ment of a tumour, resulting in a change in the physiology of 
diseased cells and subsequent cell death. Hyperthermia can 
augment the efficacy of other therapeutic modalities, such as 
irradiation, chemotherapy, surgery, gene therapy and immuno-
therapy (84-86). During hyperthermia treatment, cells undergo 
heat stress in the temperature range of 41-46˚C, resulting in 
activation and/or initiation of several intra- and extra-cellular 
degradation mechanisms, such as protein denaturation and 
aggregation, and DNA cross linking. Permanent irreversible 
protein damage can occur with a single heat treatment, resulting 
in protein aggregation and/or inhibition of many cellular func-
tions. Histological studies showed that the heating-induced 
tumour cell death was mostly achieved through necrosis rather 
than apoptosis (87). The challenge is to heat only the tumour 
mass without damaging healthy tissues.
Agostinelli and colleagues studied potential effects of both 
H2O2 and aldehyde(s) (produced by the BSAO/polyamine-
spermine enzymatic system) on the induction of cytotoxicity 
at 42˚C, rather than at 37˚C (74,79,88). In these studies, the 
most important cytotoxic metabolite of spermine was H2O2. 
In fact, H2O2, either formed by the glucose oxidase reac-
tion, or added as such to the cell suspension, was cytotoxic 
Figure 3. Ultrastructural features of mitochondria of M14 WT and M14 ADR cells (transmission electron micrographs). (a) Untreated M14 WT cells. 
(b) Untreated M14 ADR cells. (c) M14 WT cells exposed for 60 min to 6.5x10-3 IU/ml BSAO and 6 µM spermine at 37˚C. (d) M14 ADR cells, same treatment 
as in c. Bars: 0.5 µm. Panel b from Agostinelli et al (74).
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at a lower concentration than acrolein (89). In addition, H2O2 
generated in situ from hypoxanthine by reaction with xanthine 
oxidase had anti-tumour effects in vivo (90). Both H2O2 and 
aldehyde(s), formed in the presence of BSAO and spermine 
(6 µM) for 60 min of incubation at 42˚C, were responsible for 
cytotoxicity, since the addition of catalase alone did not result 
in complete protection of cells. These studies also showed 
that overexpression of P-glycoprotein (P-gp) in MDR cells did 
not confer resistance to the enzymatic oxidation products of 
spermine. This phenomenon might be caused by an earlier and 
higher mitochondrial membrane depolarization and a higher 
basal production of ROS (79,82).
Regional hyperthermia potentiates the cytotoxic action 
of many different anticancer drugs and has considerable 
potential in cancer treatment. Promising results are emerging 
from clinical studies involving hyperthermia combined with 
chemotherapy. A biological strategy to enhance the thera-
peutic effects of hyperthermia is to use heat in combination 
with pharmacological agents that show enhanced cytotoxicity 
at high temperatures. These thermosensitizer compounds, 
such as cysteamine and aminothiol N-(2-mercaptoethyl)-1,3-
propanediamine (WR-1065), are not toxic at 37˚C, but become 
inactivators of cellular function at elevated temperatures (91). 
Another group of drugs, all of which were considered to be heat 
sensitizers, are the naturally occurring polyamines putrescine, 
spermine and spermidine (92).
The enzymatic oxidation products of spermine behave in a 
manner similar to that of thermosensitizers (93,94). Beneficial 
effects could therefore be achieved using localized heating 
to enhance the action of toxic products generated by BSAO/
spermine within the tumour site, without increasing normal 
tissue damage. It was observed that the concentrations of 
spermine necessary to induce cytotoxicity were different in 
cell lines of various histotype (74,79,95,96). An interesting 
result was that an inactive combination of spermine (≤1 µM) 
and BSAO at 37˚C became cytotoxic at 42˚C for both human 
colon adenocarcinoma and melanoma cells, mimicking the 
action of thermosensitizers (74,88). These findings suggested 
a marked enhancement of cytotoxicity on LoVo and M14 cells 
induced by heat, attributed to both the enzymatic oxidation 
products of spermine, H2O2 and aldehyde(s). Although still at 
an early stage, the in situ formation of toxic compounds or 
radicals by enzyme catalysed reactions is a promising start. 
For the slow release of toxic spermine metabolites into the 
tumour, the use of BSAO conjugated to biocompatible poly-
mers is considered, as reported in Conclusions and Future 
Perspectives paragraph (73,97).
7. Nanoparticle delivery of BSAO in cancer cells
A major impediment in advancing nanotechnology to the 
clinics is the inability of nanoparticles to undergo facile trans-
port through the cell membrane. Several approaches have been 
attempted to circumvent this problem. We describe below some 
of the approaches used to transport BSAO in tumour cells.
Antitumoral effect in vitro and in vivo of native and immo-
bilized BSAO on polyethylene glycol (PEG). In previous 
studies, H2O2 and aldehydes were produced outside the cells 
and subsequently entered inside the cells, producing cytotoxic 
effects. Catalytically liberated cytotoxic agents require only 
a few enzymatic units of the protein for toxin formation, and 
the cytotoxic reaction products are continuously formed over 
an extended period of time (57,98). Since endogenous poly-
amines are present at high concentrations in tumour cells and 
growing tissues, it is expected that toxic enzymatic oxidation 
products can be produced intracellularly by delivering BSAO 
directly into the cells, thereby achieving in situ killing of cells. 
Attempts were made to incorporate the enzyme into liposomal 
vesicles (99), and prepare amine oxidase-gold complexes that 
were bound and incorporated by hepatocytes (100). Thus, 
endogenous polyamines could be targeted and oxidized by 
the enzyme. In this context, attempts were made to produce 
immobilized BSAO to increase its plasmatic half-life and 
therapeutic efficacy and to decrease drug toxicity. The enzyme 
was conjugated to a bio-compatible non-immunogenic 
polymer, polyethylene glycol (PEG), and then immobilized 
into a hydrogel-type matrix (97). Hydrogels are hydrophilic 
macromolecular networks that possess high water content. 
This feature should allow a controlled delivery of the enzyme 
by crossing the cell membrane and then, also a controlled 
release of the enzyme in the intracellular environment to 
maintain a drug concentration at therapeutic levels. Therefore, 
the immobilized BSAO exhibited considerable advantages 
over the free enzyme. Both native and immobilized BSAO 
were then compared in vivo, in terms of their respective abili-
ties to induce melanoma regression in mice by either apoptosis 
or necrosis. In fact, the growth of a mouse melanoma (B16-F0) 
was reduced by 70% after a single injection of the immobilized 
enzyme, in comparison with 32% inhibition after injection of 
the same amount of native BSAO. While the immobilized 
enzyme induced a high level (70%) of apoptosis, non-apoptotic 
cell death prevailed in the case of the native enzyme (73). 
The difference of cell death ratio was attributed to the slow, 
gradual release of spermine enzymatic oxidation products 
from the hydrogel, i.e. the long-term exposure of the tumour 
to ROS and aldehydes, as compared with the shorter, though 
more rapid release of toxic metabolites by the native enzyme.
Iron oxide nanoparticles. Nanotechnological applications 
of iron oxides, namely maghemite (γ-Fe2O3) and magnetite 
(Fe3O4), have been intensely studied in different research 
areas, such as magnetic data storage (101,102), pigment 
production (103), electrochemistry (104), biosensing (105,106), 
drug delivery and protein purification (107). Cross-linked iron 
oxide (CLIO) (108), ultra-small superparamagnetic iron oxide 
(USPIO) (109), and mono-crystalline iron oxide nanopar-
ticles (MIONs) (110) have been developed for diagnostic and 
therapeutic applications. Iron-oxide nanoparticles possess 
several superior properties, including magnetic properties 
(e.g. superparamagnetism, high values of saturation magneti-
zation, easy control by small magnetic fields) and biochemical 
(e.g. non-toxicity, biodegradability, and biocompatibility) that 
justify their role in drug delivery. The ability of iron oxide 
nanoparticles to undergo cellular phagocytosis facilitates their 
use in contrast enhanced MRI beyond vascular and tissue 
morphology imaging (111), thereby enabling novel applica-
tions of iron oxide nanoparticles for MRI based diagnosis of 
liver diseases, cancer metastasis to lymph nodes, and in vivo 
tracking of implanted cells and grafts. Functionalized and 
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engineered magnetic nanoparticles have been developed to 
meet the increasing demand for non-invasive in vivo imaging 
of molecular and cellular activities, specific to a disease state. 
Several biomarkers, such as antibodies (32), aptamers (112), 
enzymes (113), peptide fragments (114) and polysaccha-
rides (115) were used to achieve specificity and to reduce 
adverse side effects of iron oxide nanoparticles.
The possibility to convert dissipated magnetic energy 
into thermal energy led to the development and applica-
tion of magnetic materials for hyperthermia treatment of 
cancer (83,116). Magnetic nanoparticles used for hyperthermia 
are only few tens of nanometer in size and therefore, allows 
easy passage into several tumours whose pore sizes are 
in 380-780 nm range. It was also found that irradiation of 
magnetic nanoparticles with a radio-frequency (in the range 
100 kHz - 1 MHz) led to an increase in media temperature. 
This phenomenon can be used to increase the temperature of 
cells and tissue, and can be used in conjunction with hyper-
thermia for therapeutic purpose.
The controlled release of drugs with spatiotemporal control 
is the key to meeting several challenges in drug delivery appli-
cations. Controlled release of drugs from nanoparticle based 
delivery systems, triggered by a number of external stimuli, 
has been extensively studied (117). Iron oxide nanoparticles 
have the ability to act as chemotherapeutic agents to release 
drugs in a controlled manner. The most important advantage of 
nanoparticle-drug adducts, once that they have been released 
inside the cell, resides on their retention within the cell at 
concentrations sufficient to inhibit cell growth and functions, 
providing sustained drug release and improvement of treat-
ment efficacy. Moreover, the ability of short interfering RNA 
(siRNA) to silence specific genes inspired the use of siRNA as 
a therapeutic agent for a wide spectrum of disorders including 
cancer, infectious diseases, and metabolic disturbances (118). 
In order to optimize the delivery of siRNA and enhance 
the efficiency of the treatment, the preparation of magnetic 
nanoparticles for imaging and siRNA delivery specifically 
to cancer cells was proposed (119). Iron oxide nanoparticles 
may be combined with different active agents, which could be 
proposed for therapy and diagnosis (120), thereby realizing 
their potential as theranostic agents.
BSAO bound to nanosized magnetic nanoparticles. Recently, 
a novel synthetic procedure for nanostructured superparamag-
netic material in the size range approximately 10 nm, constituted 
of stoichiometric maghemite (γ-Fe2O3), and showing peculiar 
surface chemical behavior, called SAMNs (surface active 
maghemite nanoparticles) was developed (121). Maghemite 
nanoparticles and method for preparing thereof World Pat. 
WO/2012/010200). These superparamagnetic nanoparticles 
were modified with BSAO to improve the uptake, retention 
and therapeutic efficacy of BSAO. Fluorescent and magneti-
cally drivable adducts comprising of BSAO and iron oxide 
had a diameter of 10±2 nm (SAMN@RITC-BSAO). These 
nanocatalyts are characterized by specific chemical behaviour 
and combine the advantages of immobilized enzymes with 
magnetic properties and a fluorescent probe (121) (Fig. 4). 
The multifunctional nanomaterial has been characterized 
by transmission electron microscopy (Fig. 5), infrared mass 
spectrometry and enzyme activity measurements. The immo-
bilized enzyme partially retains its catalytic activity toward 
polyamine oxidation.
Further investigations showed that bare magnetic nanopar-
ticles form stable colloidal suspension in aqueous solutions. 
The maximum binding capacity of BSAO was ~6.4 mg g-1 
nanoparticles. However, the immobilization procedure reduced 
the catalytic activity by ~40%, compared to the activity of 
native enzyme. There was a 2-fold increase in the Michaelis 
constant of the enzyme. Taken together, these magnetically 
drivable nanocatalysts with a fluorescent tag and a specific 
activity of 0.81 IU g-1 are used in the presence of polyamines 
for selective killing of tumour cells by the in situ production of 
H2O2 and aldehydes (122).
Figure 4. Schematic representation of fluorescent and magnetically drivable 
adduct comprising BSAO immobilized on the surface of specifically func-
tionalized magnetic nanoparticles. Figure 5. TEM image of maghemite nanoparticles derivatized with RITC and immobilized BSAO (SAMN@RITC-BSAO), as shown in Fig. 3. From 
Sinigaglia et al (122).
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8. Conclusions and future perspectives
Nanotechnology promises major advances in drug delivery, 
retention and efficacy as well as in diagnostic imaging. Hence 
these particles are theranostic agents. Gene delivery requires 
the transport of DNA through the cell membrane. DNA 
condensation to nanoparticles is a pre-requisite for facile 
transport of DNA. Oligonucleotide based DNA structures 
have been designed as drug delivery vehicles. Polyamines 
are excellent promoters of DNA condensation and inves-
tigations into polyamine structure-activity relationship in 
DNA condensation and transport continues to be an active 
area of research (123). Numerous studies have demonstrated 
that H2O2 and other reactive oxygen species are capable of 
blocking cells in G1, S or G2 phases of the cell cycle and 
inhibiting cell growth (124). Utilization of amine oxidase 
enzymes, especially BSAO can make clinical advances 
in the future. However, therapeutic applications of radical 
generating systems are still at the beginning. It is our hope 
that the utilization of amine oxide activity in the presence 
of biogenic amines will turn out to be a powerful strategy 
in the development of new anticancer treatments (73). Since 
hyperthermia is a clinically established therapeutic method, 
strategies should be developed that combine hyperthermia 
with extracellular ROS formation. In support of this idea is 
the fact that a marked enhancement of cytotoxicity, attributed 
to H2O2 and spermine-derived aldehyde(s) has been observed 
by elevating the temperature of tumour cell cultures from 
37˚C to 42˚C (74,88,125).
This approach showed a higher sensitivity of MDR 
human adenocarcinoma and melanoma cells toward cytotoxic 
spermine metabolites, H2O2 and aldehydes, compared to the 
action of these agents on wild-type counterparts of these 
cells. This finding has been attributed to an early and higher 
mitochondrial membrane depolarization, and a higher basal 
production of ROS (82). In fact, H2O2 could directly interact 
with some iron of Fe/S centres located in the respiratory chain, 
raising the highly reactive hydroxyl radical (HO•) by means of 
Fenton reaction, which induces oxidation of some thiol (SH) 
groups, proteins and lipids. Thus, hyperthermia combined with 
either toxic BSAO/polyamine metabolites or with thermosen-
sitizing drugs is of great interest to develop a new strategy 
to overcome MDR of cancer cells. Iron oxide nanoparticles 
are important theranostic particles since they can be surface 
modified with reactive groups, antibodies and fluorescent 
molecules. BSAO immobilization was carried out on PEG 
and superparamagnetic nanoparticles. Moreover, a recent new 
strategy showed an increase in the stability of the enzyme and 
an improvement in releasing cytotoxic products. BSAO was 
conjugated on a new injectable nanohydrogel (NH), obtained 
by derivatizing hyaluronic acid (HA) with cholesterol (CH). 
The high immobilizing capacity of the HA-based anionic NHs 
with BSAO and retention of the catalytic activity allows the use 
of the immobilized enzyme BSAO as heterogeneous catalyst 
of a plug flow microreactor of H2O2 and aldehyde, inserted into 
a flow injection analysis system. The HA-based NH complex 
is a useful controlled delivery system for future therapeutic 
enzymes application (126). However, all the resulting systems 
were stable and bioactive, with respect to the free BSAO, indi-
cating how this approach might represent a promising tool in 
anticancer therapy, for inducing an apoptotic effect on human 
cancer treatment.
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